What the Business Does
Elevance Health, Inc. (ELV) operates within the healthcare sector, specifically focusing on healthcare plans. The company provides a range of health benefits and services designed to improve health outcomes for its members. As a major player in the industry, Elevance Health leverages its significant market capitalization of approximately $88.37 billion to maintain a competitive edge.
The Buffett-Framework Verdict
Using the Buffett framework, Elevance Health scores a "C" grade, with an overall score of 44, suggesting it does not meet the framework's criteria for a strong investment. The framework highlights several strengths, such as a steady revenue CAGR of 8.34% over the last five years and a commitment to returning capital to shareholders through a dividend CAGR of 8.48%. However, concerns include its low operating margin of 3.81% and a return on invested capital (ROIC) of 8.65%, which is below the preferred threshold of 15%.
For more on how Elevance Health measures up in the Buffett framework, see the Buffett verdict.
Valuation and Margin of Safety
Elevance Health's current price is $407.50, with a price-to-earnings (P/E) ratio of 14.29. This valuation is reasonable when considering its industry and market position. However, the analyst target price is $382.38, suggesting limited upside potential. The company's net margin of 2.84% and gross margin of 23.16% are both below sector averages, indicating potential challenges in achieving higher profitability.
The Bull Case
The bullish perspective on Elevance Health centers around its scale and consistent financial performance. The company's ability to repurchase shares, as evidenced by a share count CAGR of -2.56%, is a positive indicator of management's confidence in the business. Additionally, its interest coverage ratio of 5.8 demonstrates solid financial health, allowing it to service its debt obligations effectively. The company's steady dividend growth also attracts income-focused investors.
The Bear Case
On the downside, Elevance Health faces significant competitive pressures within the healthcare sector, which is reflected in its low operating and gross margins. The company's net debt/EBITDA ratio of 2.34 is above the preferred maximum of 2x, indicating higher financial leverage. Furthermore, its owner earnings yield of 3.92% falls short of the 8-10% range typically desired by value investors.
The Bottom Line
Elevance Health presents a mixed investment case. While it benefits from its market size and steady revenue growth, its profitability metrics and competitive positioning raise concerns. Investors should weigh these factors carefully before making a decision.
For a deeper dive into Elevance Health's financials, visit the stock page.
This is educational, not financial advice.